Lauryl Gallate Hemostatic Agent for Platelet Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for controlling bleeding in emergency or medical settings are either ineffective, costly, or require medical expertise, and there is a lack of understanding of the effects of Lauryl gallate (LG) on hemostasis and thrombosis.
Innovation Solution
Lauryl gallate (LG) is used as a hemostatic agent to induce platelet aggregation and promote blood clotting by modifying membrane lateral organization, activating signaling pathways, and increasing calcium influx, thereby effectively arresting bleeding at wound sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional hemostatic methods are used, then bleeding control is achieved, but cost increases or medical expertise is required
Solution Approach 1:
The patent employs lauryl gallate, a low-cost food additive already approved for human consumption, as a disposable hemostatic agent. This eliminates the need for expensive, complex medical devices or specialized equipment, making the solution accessible for non-medical personnel while maintaining effectiveness in controlling bleeding.
Solution Approach 2:
The patent replicates the hemostatic effect of complex medical coagulation factors using a simple, naturally occurring compound (lauryl gallate). By copying the essential function of expensive medical products with a low-cost alternative, the invention makes effective bleeding control available without requiring medical expertise or expensive resources.
2Reliability
If Lauryl gallate is used to promote platelet aggregation, then hemostatic effect is improved, but thrombotic risk may increase
Solution Approach 1:
The patent applies lauryl gallate locally at the wound site rather than systemically throughout the body. This localized application ensures that platelet aggregation and hemostatic effects are concentrated where needed (at the bleeding site) while minimizing systemic exposure that could cause unwanted thrombotic events in other parts of the circulation.
Solution Approach 2:
The patent uses low concentrations of lauryl gallate that are sufficient to achieve the desired hemostatic effect at the wound site without excessive activation of coagulation pathways. By applying just enough agent to stop bleeding locally, the invention avoids over-activation that could lead to pathological thrombosis while still achieving reliable hemostasis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
LG demonstrates potent antihemorrhagic properties by reducing bleeding time and blood loss, with potential for use in various surgical and emergency scenarios without the need for medical qualification, while minimizing thrombotic risks.
Implementation Method 1
LG, possibly through its capacity to modify membrane lateral organization, has pro-aggregant and antihemorrhagic properties
Implementation Method 2
LG induced a dramatic platelet membrane modification associated with calcium influx and a slow platelet aggregation response
Implementation Method 3
LG at a low concentration has the ability to spontaneously induce washed human platelet shape change, filopodia emission, granule secretion, phosphatidylserine expression and aggregation
Data Source
AI summary
The food additive lauryl gallate (LG, E312) is a molecule with antioxidant and hydrophobic properties which has also been shown to exert antibacterial, antiviral and anti-tumoral effects. Here, the inventors show that LG at a low concentration has the ability to spontaneously induce washed human platelet shape change, filopodia emission, granule secretion, phosphatidylserine expression and aggregation. LG was able to activate intracellular signaling pathways including Akt, p38MAP-kinase and calcium response and to trigger activation of the αIIbβ3 integrin. LG also significantly potentiated platelet aggregation induced by low doses of collagen or thrombin receptor agonist peptide. Consistent with this, low doses of LG added to human blood promoted a strong platelet thrombotic response under arterial flow on a collagen matrix. As shown by electron microscopy, at a high concentration, LG induced a dramatic platelet membrane modification associated with calcium influx and a slow platelet aggregation response. Finally, a local flash-application of LG efficiently decreased the tail bleeding in rats suggesting that this compound has the potential to act as a hemostatic. Overall, the results indicate that the food additive LG, possibly through its capacity to modify membrane lateral organization, has pro-aggregant and antihemorrhagic properties.